Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
- Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise
- 3Q23 DAYBUE™ (trofinetide) net product sales of $66.9 million
- 3Q23 NUPLAZID® (pimavanserin) net product sales of $144.8 million
https://www.businesswire.com/news/home/20231102863530/en/
DAYBUE BOOOOOM !!!!!!!!!!!
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$23.97 |
Change
3.260(15.7%) |
Mkt cap ! $3.060B | |||
| Open | High | Low | Value | Volume |
| $23.00 | $24.00 | $21.60 | $27.11M | 1.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 942 | $23.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $23.97 | 27 | 1 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$24.00 |
Change
3.260 ( 16.0 %) |
||||
| Open | High | Low | Volume | ||
| $22.98 | $24.00 | $21.60 | 310545 | ||
| Last updated 15.59pm 27/05/2024 ? | |||||
| NEU (ASX) Chart |